Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...
AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...
Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...
Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...
Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...
Hosted on MSN6mon
FDA grants full approval to AbbVie/ImmunoGen drug ElahereThe FDA has granted full approval for AbbVie’s (NYSE:ABBV) drug Elahere for the treatment of ovarian cancer. AbbVie said the drug was approved to treat folate receptor alpha-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback